Okpo Health - Früherkennung bei Prostatakrebs ?
Seite 7 von 25 Neuester Beitrag: 25.04.21 02:34 | ||||
Eröffnet am: | 13.02.14 19:16 | von: Spaetschicht | Anzahl Beiträge: | 624 |
Neuester Beitrag: | 25.04.21 02:34 | von: Kristinvpuka | Leser gesamt: | 229.588 |
Forum: | Börse | Leser heute: | 11 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 4 | 5 | 6 | | 8 | 9 | 10 | ... 25 > |
http://www.opkorenal.com/pipeline/product_candidates.html
by Phil Early on June 12, 2015
http://www.insidertradingreport.org/...nelli-buys-4175-shares/611241/
Form 4 Opko Health, Inc. For: Jun 09 Filed by: Frost Gamma Investments Trust
http://www.streetinsider.com/SEC+Filings/...ments+Trust/10639804.html
Richard A Lerner Buys 12,500 Shares
http://www.insidertradingreport.org/...erner-buys-12500-shares/66863/
http://www.smarteranalyst.com/2015/06/26/...e-cancer-early-detection/
15.15 26.08.15
MIAMI - (BUSINESS WIRE) -
OPKO Health, Inc. (NYSE: OPK) hat heute die folgenden offenen Brief von Phillip Frost, MD, Chairman und Chief Executive Officer, an die Aktionäre:
Sehr geehrte Aktionäre,
Ich möchte die Gelegenheit OPKO kürzlich angekündigten Akquisition von Bio-Reference Laboratories (Bio-Referenz) zu ergreifen, um einen allgemeinen Überblick über vorliegende Aktivitäten des Unternehmens zu präsentieren. Sie sind zahlreich und während in einigen Hinsichten stark voneinander, alle ein gemeinsames Thema unterscheiden sie sich. Sie alle befassen sich mit Produkten für große Märkte, in denen OPKO hat die Möglichkeit, ein Führer zu sein, und alle haben Potenzial für langfristiges Wachstum. Wir hoffen, dass dieses Wachstum durch eine immer größere Spektrum der Medikamente und Tests, einige neue und neuartige, andere von bereits etablierten Wert, um Ärzte eine bessere Versorgung für ihre Patienten zu erreichen....
Ganzer Text:
https://translate.google.de/...to-Shareholders-5469637&edit-text=
Consolidated Revenue Increased to $143.0 Million From $19.8 million for the Three Months Ended September 30, 2015, and Increased to $215.5 Million from $65.6 Million for the Nine Months Ended September 30, 2015
Closed Acquisition of Bio-Reference Laboratories on August 20, 2015
Announced Genomics Collaboration with Vanderbilt University School of Medicine
4Kscore® Blood Test to Identify Risk of Aggressive Prostate Cancer Included in the National Comprehensive Cancer Network Guidelines for Cancer Early Detection
RayaldeeTM New Drug Application (NDA) Accepted by FDA; Expected PDUFA Date is March 29, 2016
Completed Enrollment in hGH-CTP Phase 3 Trial in Growth Hormone Deficient Adults
Presented Positive 12-month Clinical Data on hGH-CTP Phase 2 Trial in Growth Hormone Deficient Children
Reported New Preclinical Data Supporting Subcutaneous Administration for Long-Acting Factor VIIa-CTP for Hemophilia; Phase 2a Clinical Trial of Long Acting IV Form Expected to Commence in Q4 2015
Phase 1 Clinical Trial for Long-Acting Subcutaneous Oxyntomodulin for Obesity and Diabetes Expected to Commence in Q1 2016
VARUBI™ (rolapitant) Approved by the FDA; Commercial Sales Expected to Commence this Month by TESARO with OPKO Eligible to Receive Up To an Additional $110 Million of Milestone Payments Plus Ongoing Royalties
MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, today reported financial and operating results for the three and nine months ended September 30, 2015.
9.95 -0.01 (-0.10%)
After Hours: 10.31 +0.36 (3.62%)
Nov 9, 4:31PM EST
NYSE real-time data - Disclaimer
Currency in USD
OPKO Health (OPK +5%) Q3 results: Revenues: $143M (+622.2%); Costs and Expenses: $151.3M (+122.5%); Operating Loss: ($8.3M) (+82.8%); Net Income: $128.2M (+363.2%); EPS: $0.25 (+327.3%); Quick Assets: $212.1M (+118.9%).
No guidance given.
VARUBI is a substance P/neurokinin-1 (NK-1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. NK-1 receptors are highly concentrated in the brain and bind neurokinin substance P. Activation of NK-1 receptors plays a central role in nausea and vomiting induced by emetogenic stimuli, including certain cancer chemotherapies. A Positron Emission Tomography (PET) study with rolapitant in normal, healthy volunteers demonstrated that rolapitant crosses the blood brain barrier and occupies brain NK-1 receptors at high levels for up to 120 hours. VARUBI has a half-life of approximately seven days, which may contribute to the ability of a single dose of VARUBI to cover the entire delayed CINV phase (25-120 hours).
Sogar die Prognose das man ab 2017 schwarze Zahlen schreibt wurde übertroffen. Der Wert macht einfach Spaß...
According to Insider Monkey’s hedge fund database, Tang Capital Management, managed by Kevin C. Tang, holds the biggest position in Opko Health Inc. (NYSE:OPK). Tang Capital Management has a $20.8 million position in the stock, comprising 7.7% of its 13F portfolio. Coming in second is AQR Capital Management, managed by Cliff Asness, which holds a $13.3 million position; the fund has less than 0.1% of its 13F portfolio invested in the stock. Other professional money managers that hold long positions encompass Ken Griffin’s Citadel Investment Group, D E Shaw, and Hal Mintz’s Sabby Capital.